Literature DB >> 22252482

Blood pressure and medication changes following adrenalectomy for unilateral primary aldosteronism: a follow-up study.

Petra van der Linden1, Olivier Steichen, Franck Zinzindohoué, Pierre-François Plouin.   

Abstract

OBJECTIVE: Adrenalectomy for unilateral primary aldosteronism cures hypertension in less than 50% of patients, but improvement is observed in most of the remaining ones. Our goal was to quantify the blood pressure (BP) decrease adjusted for medication changes following adrenalectomy and to identify preoperative predictors of this outcome.
METHODS: We analyzed simultaneous changes in BP and medication by reviewing the records of 156 consecutive patients who had undergone adrenalectomy for unilateral primary aldosteronism in one center between 2001 and 2009 for whom postoperative follow-up data were available.
RESULTS: Median [interquartile range] baseline SBP was 149 [135-160] mmHg on drugs from two [1-3] different classes. After adrenalectomy, SBP decreased by 21 [5-31] mmHg and the number of drug classes administered, by one [0-2]. The decrease in SBP, adjusted for the change in the number of drug classes, was 26 [14-36] mmHg. Each drug class dropped after surgery was equivalent to a 5 mmHg SBP decrease. Patients with higher preoperative BP or serum sodium levels experienced a greater BP decrease after adrenalectomy. Adrenalectomy cured hypertension in 68 (44%) patients. Hypertension was less likely to be cured in patients with a longer history of hypertension, higher preoperative BP levels, larger number of drug classes, or lower urinary aldosterone levels.
CONCLUSION: Although patients with severe hypertension are likely to derive considerable benefits from adrenalectomy in terms of BP or treatment reduction, they should be warned that hypertension cure is unlikely.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22252482     DOI: 10.1097/HJH.0b013e328350225d

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  7 in total

Review 1.  Postoperative outcomes of minimally invasive adrenalectomy: do body mass index and tumor size matter? A single-center experience.

Authors:  Felipe Girón; Carlos Eduardo Rey Chaves; Lina Rodríguez; Roberto Javier Rueda-Esteban; Ricardo E Núñez-Rocha; Sara Toledo; Danny Conde; Juan David Hernández; Marco Vanegas; Ricardo Nassar
Journal:  BMC Surg       Date:  2022-07-19       Impact factor: 2.030

Review 2.  Management of hypertension in primary aldosteronism.

Authors:  Anna Aronova; Thomas J Fahey; Rasa Zarnegar
Journal:  World J Cardiol       Date:  2014-05-26

3.  Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.

Authors:  Carrie C Lubitz; Konstantinos P Economopoulos; Stephen Sy; Colden Johanson; Heike E Kunzel; Martin Reincke; G Scott Gazelle; Milton C Weinstein; Thomas A Gaziano
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-11-10

4.  Adrenalectomy Improves the Long-Term Risk of End-Stage Renal Disease and Mortality of Primary Aldosteronism.

Authors:  Ying-Ying Chen; You-Hsien Hugo Lin; Wei-Chieh Huang; Eric Chueh; Likwang Chen; Shao-Yu Yang; Po-Chih Lin; Lian-Yu Lin; Yen-Hung Lin; Vin-Cent Wu; Tzong-Shinn Chu; Kwan Dun Wu
Journal:  J Endocr Soc       Date:  2019-03-25

5.  Accurate Location of Catheter Tip With the Free-to-Total Metanephrine Ratio During Adrenal Vein Sampling.

Authors:  Foteini Christou; Edward Pivin; Alban Denys; Karim A Abid; Tobias Zingg; Maurice Matter; Antoinette Pechère-Bertschi; Marc Maillard; Eric Grouzmann; Gregoire Wuerzner
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-24       Impact factor: 5.555

6.  Predictive factors of clinical success after adrenalectomy in primary aldosteronism: A systematic review and meta-analysis.

Authors:  Worapaka Manosroi; Pichitchai Atthakomol; Phichayut Phinyo; Piti Inthaphan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-18       Impact factor: 6.055

Review 7.  Hypertension outcomes of adrenalectomy in patients with primary aldosteronism: a systematic review and meta-analysis.

Authors:  Yu Zhou; Meilian Zhang; Sujie Ke; Libin Liu
Journal:  BMC Endocr Disord       Date:  2017-10-03       Impact factor: 2.763

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.